$0.04 $0.00 (0.0%)

11:49 AM EST on 11/15/19

HARBOR BIOSCIENCES COM USD0.01 (NASDAQOTH:HRBR)

CAPS Rating: No stars

A development stage pharmaceutical company, is engaged in the discovery, development and commercialization of products for the treatment of diseases and disorders in which the body is unable to mount an appropriate immune response.

Current Price $0.04 Mkt Cap $2.0M
Open $0.04 P/E Ratio 0.00
Prev. Close $0.04 Div. (Yield) $0.00 (0.0%)
Daily Range $0.04 - $0.04 Volume 10,000
52-Wk Range $0.02 - $0.07 Avg. Daily Vol. 30,940

Caps

This ticker is not currently Ratable.

Add Stock to CAPS Watchlist

All Players

33 Outperform
0 Underperform
 

All-Star Players

1 Outperform
0 Underperform
 

Wall Street

1 Outperform
0 Underperform
 

Top NASDAQOTH:HRBR Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

NetscribeHealthC (64.70)
Submitted February 26, 2007

Hollis-Eden is a biopharmaceutical company engaged in discovery, development and commercialization of a proprietary class of hormonal signaling compounds designed to treat diseases and disorders that arise from the disruption of cell signaling… More

Top Bear Pitch

There are no pitches that meet the Top Bear criteria. Explain

If this upsets you, start recommending pitches below!

NASDAQOTH:HRBR VS S&P 500 (SPY)

Fools bullish on NASDAQOTH:HRBR are also bullish on:

Recent Community Commentary

Read the most recent pitches from players about HRBR.

Recs

1
Member Avatar NetscribeHealthC (64.70) Submitted: 2/26/2007 7:23:49 AM : Outperform Start Price: $5.49 NASDAQ OTHER:HRBR Score: -226.44

Hollis-Eden is a biopharmaceutical company engaged in discovery, development and commercialization of a proprietary class of hormonal signaling compounds designed to treat diseases and disorders that arise from the disruption of cell signaling pathways. The company’s proprietary position in small molecule derivatives and analogs of metabolites of dehydroepiandrosterone (DHEA) is driven by its years of research in immune regulating hormones.

The company's lead product candidate, Neumune (HE2100), being developed in support from the US Military, is in late-stage development for the treatment of Acute Radiation Syndrome (ARS), a condition resulting from exposure to high levels of radiation following a nuclear or radiological incident. Numerous animal studies and endorsements by the Armed Forces Radiobiology Research Institute make Neumune as the best option against ARS, which is in the lead position to win a BioShield contract award from the Department of Health and Human Services (HHS) for the procurement of Neumune as an ARS countermeasure.

Hollis-Eden has also developed second-generation compounds using its Hormonal Signaling Technology (HST) Platform and identified candidates with greater potency and desirable pharmaceutical properties with potentially greater efficacy in humans. In 2006, the company profiled a number of these promising second-generation candidates in preclinical models of hematopoiesis, cancer, metabolic disorders, pulmonary disease and a variety of autoimmune conditions.

For the nine months ended September 2006, Hollis-Eden's revenues jumped to $204,000 from $5,000 reflecting the presence of contract research and development service revenues under Study Funding Agreement with Cystic Fibrosis Foundation. Thus, the company appears to be a likely outperformer on the back of a prospective BioShield contract, worth a funding between $100-$200 million, gaining the monetary potential in its significant intellectual property in the HST Program with out-licensing partnership and an emerging pipeline in clinical testing.

Recs

0
Member Avatar pistolpete2 (< 20) Submitted: 12/21/2006 10:29:35 PM : Outperform Start Price: $5.22 NASDAQ OTHER:HRBR Score: -233.11

watch for a big jump in share price by Jan. 31, 2007.

Recs

0
Member Avatar ac1091caps (< 20) Submitted: 12/14/2006 7:13:31 AM : Outperform Start Price: $5.69 NASDAQ OTHER:HRBR Score: -232.81

radiation remediation. In case of dirty bomb attack, this stock is it.

Leaderboard

Find the members with the highest scoring picks in HRBR.

Score Leader

CVMp

CVMp (87.43) Score: +73.33

The Score Leader is the player with the highest score across all their picks in HRBR.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
Index
Gain
Score Commentary
NetscribeHealthC 64.70 2/26/2007 Outperform 1Y $5.49 -99.33% +127.11% -226.44 1 Comment
hinterlander < 20 12/28/2006 Outperform 1Y $5.33 -99.31% +132.57% -231.87 0 Comment
gobigalways < 20 1/3/2007 Outperform 3W $5.35 -99.31% +132.83% -232.13 0 Comment
dodgydow < 20 1/3/2007 Outperform 3W $5.35 -99.31% +132.83% -232.13 0 Comment
DISARONNO < 20 12/7/2006 Outperform NS $5.49 -99.33% +132.96% -232.29 0 Comment
yogas 30.21 12/29/2006 Outperform 3M $5.32 -99.30% +133.16% -232.47 0 Comment
ac1091caps < 20 12/14/2006 Outperform 3Y $5.69 -99.35% +133.46% -232.81 1 Comment
pistolpete2 < 20 12/22/2006 Outperform 3W $5.22 -99.29% +133.82% -233.11 1 Comment
ritasbabe12 26.31 12/8/2006 Outperform 3Y $5.40 -99.31% +134.72% -234.03 1 Comment
RankAm 24.44 12/8/2006 Outperform NS $5.40 -99.31% +134.72% -234.03 0 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

There are no Wall Street tracker picks for HRBR.